Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) edging 0.03% higher and the iShares Biotechnology ETF (IBB) up 0.3%.

Arcus Biosciences (RCUS) stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.

Precigen (PGEN) shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.

Tvardi Therapeutics (TVRD) shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.